Form 4: Cadrenal Therapeutics COO Awarded Stock Options

Cadrenal Therapeutics' Chief Operating Officer, Jeffrey Scott Cole, was granted 25,000 stock options on January 23, 2025.

Summary

• Jeffrey Scott Cole, the Chief Operating Officer of Cadrenal Therapeutics, Inc., was granted 25,000 stock options.
• The options have an exercise price equal to the fair market value of the company's common stock on the grant date.
• The options vest 1/4 on February 1, 2026, and then pro rata monthly over the following three years.
• The vesting is contingent upon Mr. Cole's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive for aligning management and shareholder interests. There are no negative implications.

Positives

• The stock option grant aligns the COO's interests with the company's long-term performance.
• The vesting schedule encourages continued service and commitment from the COO.

Risks

• The value of the options is dependent on the future performance of Cadrenal Therapeutics' stock.
• If Mr. Cole leaves the company before the options fully vest, he may forfeit some or all of them.

Future Outlook

The stock options will vest over the next three years, contingent on the COO's continued employment.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
• Vesting schedules, like the one described, are typical to ensure long-term commitment from key personnel.
• The specific terms of the grant, such as the exercise price and vesting schedule, are generally aligned with industry norms for companies of similar size and stage.

Stakeholder Impact

• Shareholders may view this as a positive incentive for the COO to drive company performance.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, Cadrenal Therapeutics, executive compensation, insider trading, Jeffrey Scott Cole, COO, vesting